[{"orgOrder":0,"company":"Phebra","sponsor":"BioSenic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2024","type":"Agreement","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Preclinical","graph3":"Phebra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phebra \/ BioSenic","highestDevelopmentStatusID":"4","companyTruncated":"Phebra \/ BioSenic"}]

Find Clinical Drug Pipeline Developments & Deals by Phebra

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : The agreement aims for the development of the first oral formulation of ArsciCor (arsenic troxide) in the field of several targeted autoimmune diseases, including for cGvHD treatment.

                          Product Name : ArsciCor

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Undisclosed

                          January 15, 2024

                          Lead Product(s) : Arsenic Trioxide

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : BioSenic

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank